114 related articles for article (PubMed ID: 33369923)
1. Eltrombopag-Associated Cerebral Venous Thrombosis.
Khattak T; Mitwalli MY; Ubaid A; Shoukry A; Anjum S
Am J Ther; 2021 Jan-Feb 01; 28(1):e167-e169. PubMed ID: 33369923
[No Abstract] [Full Text] [Related]
2. Extensive cerebral venous sinus thrombosis following a dose increase in eltrombopag in a patient with idiopathic thrombocytopenic purpura.
Mulla CM; Rashidi A; Levitov AB
Platelets; 2014; 25(2):144-6. PubMed ID: 23320857
[No Abstract] [Full Text] [Related]
3. Eltrombopag: How secure in triple therapy of HCV?
Kayar Y; Danalioglu A; Kocaman O; Baysal B; Senturk H
Acta Gastroenterol Belg; 2015 Dec; 78(4):445-6. PubMed ID: 26712061
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction.
Gunes H; Kivrak T
Curr Drug Saf; 2016; 11(2):174-6. PubMed ID: 26560493
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous thrombosis associated with eltrombopag treatment for immune thrombocytopenia.
Iinuma S; Nagasawa Y; Sasaki K; Hayashi K; Kanno K; Honma M; Sugawara M; Kinouchi M; Obata M; Ishida-Yamamoto A
J Dermatol; 2020 Feb; 47(2):e57-e58. PubMed ID: 31782189
[No Abstract] [Full Text] [Related]
6. Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.
Nguyen TT; Palmaro A; Montastruc F; Lapeyre-Mestre M; Moulis G
Drug Saf; 2015 Dec; 38(12):1179-86. PubMed ID: 26338346
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag-associated hyperpigmentation.
Braunstein I; Wanat KA; Elenitsas R; Xu X; Frey N; Rosenbach M
JAMA Dermatol; 2013 Sep; 149(9):1112-5. PubMed ID: 23884150
[No Abstract] [Full Text] [Related]
8. Eltrombopag for the Treatment of Immune Thrombocytopenia: The Aegean Region of Turkey Experience.
Özdemirkıran F; Payzın B; Kiper HD; Kabukçu S; Akgün Çağlıyan G; Kahraman S; Sevindik ÖG; Ceylan C; Kadıköylü G; Şahin F; Keskin A; Arslan Ö; Özcan MA; Kabukçu G; Görgün G; Bolaman Z; Büyükkeçeci F; Bilgir O; Alacacıoğlu İ; Vural F; Tombuloğlu M; Gökgöz Z; Saydam G
Turk J Haematol; 2015 Dec; 32(4):323-8. PubMed ID: 25914025
[TBL] [Abstract][Full Text] [Related]
9. Severe cutaneous toxicity related to Eltrombopag.
Meyer SC; Rovó A; Tsakiris DA; Scherer K; Tichelli A; Holbro A
Br J Haematol; 2013 Feb; 160(3):412-4. PubMed ID: 23151239
[No Abstract] [Full Text] [Related]
10. [Case report; a thromboembolic event in a patient with antiphospholipid antibody associated thrombocytopenia during eltrombopag therapy].
Kanda M; Kondo M; Yamamoto S; Mukai M
Nihon Naika Gakkai Zasshi; 2013 Jun; 102(6):1461-3. PubMed ID: 23947214
[No Abstract] [Full Text] [Related]
11. No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study.
Lafaurie M; Baricault B; Soler V; Cassagne M; Sailler L; Lapeyre-Mestre M; Sommet A; Moulis G
Br J Haematol; 2020 May; 189(4):e137-e140. PubMed ID: 32155284
[No Abstract] [Full Text] [Related]
12. Cardiac and pulmonary thrombosis during multidrug treatment in an idiopathic thrombocytopenic purpura patient.
Andic N; Gunduz E; Akay OM; Şahin D; Teke HÜ
Platelets; 2014; 25(1):69-70. PubMed ID: 23320868
[TBL] [Abstract][Full Text] [Related]
13. Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009-2013 French PharmacoVigilance assessment.
Moulis G; Bagheri H; Sailler L; Jonville-Bera AP; Weber E; Guy C; Petitpain N; Laroche ML; Favrelière S; Béné J; Baldin B; Villeval-Federici L; Tebacher-Alt M; Bres V; Veyrac G; Grandvuillemin A; Mauprivez C; Lapeyre-Mestre M; Montastruc JL;
Eur J Intern Med; 2014 Oct; 25(8):777-80. PubMed ID: 25242516
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag: liver toxicity, kidney injury or assay interference?
Choy KW; Wijeratne N; Doery JC
Pathology; 2016 Dec; 48(7):754-756. PubMed ID: 27780601
[No Abstract] [Full Text] [Related]
15. Sudden blindness due to bilateral central retinal artery occlusion in a patient on eltrombopag.
Au WY; Ma ES; Chow PC; Kan YT
Ann Hematol; 2014 May; 93(5):881-2. PubMed ID: 24048635
[No Abstract] [Full Text] [Related]
16. Eltrombopag-Associated Acneiform Rash: A Case Report.
Cobert AM; Wall JG; Moore DC
Am J Ther; 2021 Mar-Apr 01; 28(2):e245-e246. PubMed ID: 31567158
[No Abstract] [Full Text] [Related]
17. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
18. Morbilliform eruption related to eltrombopag: emerging data on the cutaneous toxicity of thrombopoietin receptor agonists.
Kazemi T; Martin S; Worswick S
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617608
[TBL] [Abstract][Full Text] [Related]
19. [Safety and efficacy of the use of eltrombopag in a case of severe acquired bone marrow aplasia].
Rubio-San-Simón A; Lázaro Rodríguez I; Vázquez Gómez F; Vivanco Martínez JL; Pérez Alonso V
An Pediatr (Engl Ed); 2019 Apr; 90(4):246-247. PubMed ID: 29798814
[No Abstract] [Full Text] [Related]
20. Eltrombopag in chronic idiopathic thrombocytopenic purpura.
Panzer S; Pabinger I
Lancet; 2009 Feb; 373(9664):607-8. PubMed ID: 19231614
[No Abstract] [Full Text] [Related]
[Next] [New Search]
